Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Denali Therapeutics Inc. - Common Stock
(NQ:
DNLI
)
16.27
-0.24 (-1.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,185,505
Open
16.66
Bid (Size)
16.00 (1,000)
Ask (Size)
16.40 (200)
Prev. Close
16.51
Today's Range
15.69 - 16.68
52wk Range
10.57 - 24.34
Shares Outstanding
121,640,069
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
December 30, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More
↗
December 10, 2025
Via
The Motley Fool
Performance
YTD
N/A
N/A
1 Month
-18.5%
-18.5%
3 Month
+6.9%
+6.9%
6 Month
+14.2%
+14.2%
1 Year
-17.9%
-17.9%
More News
Read More
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 09, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 04, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Board and Executive Leadership Updates
November 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate
↗
October 14, 2025
Via
Benzinga
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
October 13, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 11, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
July 07, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
May 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
What Happened To Denali Therapeutics Stock Wednesday?
↗
April 02, 2025
Via
Benzinga
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
April 02, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
↗
March 06, 2025
Via
Benzinga
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 27, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
↗
January 15, 2025
Via
Benzinga
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 13, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
January 08, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
↗
January 07, 2025
Via
Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
↗
January 07, 2025
Via
Investor's Business Daily
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
January 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Denali Therapeutics Inc. - Common Stock publicly traded?
Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Denali Therapeutics Inc. - Common Stock trade on?
Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?
The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market
What is the current price of Denali Therapeutics Inc. - Common Stock?
The current price of Denali Therapeutics Inc. - Common Stock is 16.27
When was Denali Therapeutics Inc. - Common Stock last traded?
The last trade of Denali Therapeutics Inc. - Common Stock was at 01/02/26 04:00 PM ET
What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
The market capitalization of Denali Therapeutics Inc. - Common Stock is 1.98B
How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
Denali Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
